Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Ashoka Changemakers announced that thirteen finalists have been selected in the first Boehringer Ingelheim Making More Health competition.
Lundbeck and Otsuka Pharmaceutical sign historic agreement
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced a development and commercialisation agreement for up to five products in the psychiatry field, including aripiprazole depot formulation and OPC-34712 from Otsuka and up to three highly innovative earlier stage projects from Lundbeck.
Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.
Lundbeck's third quarter report 2011 - The positive momentum continues
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports third quarter revenue of DKK 3,975 million, an increase of 10% compared to the same quarter last year. The growth was driven by increasing revenue from key products and a milestone payment related to the launch of escitalopram in Japan.
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
- Details
- Category: Novartis
Novartis announced the appointment of Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals effective immediately.
Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits
- Details
- Category: Pfizer
Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus
New Structure of Business Operations for a Global Pharmaceutical Company
- Details
- Category: Takeda
As part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture".
More Pharma News ...
- PATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition
- ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership
- Sanofi net sales up 10.1% and Business net income up 4.1% at CER
- Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
- Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Pfizer Reports Third-Quarter 2011 Results
- Daiichi Sankyo Establishes New Vaccine Research Unit in Japan